가성뇌종양 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pseudotumor cerebri market size is expected to grow from USD 4.52 billion in 2025 to USD 4.87 billion in 2026 and is forecast to reach USD 7.07 billion by 2031 at 7.73% CAGR over 2026-2031.

This report is Segmented by Offering (Treatment [Medication and More], Diagnostic Modality [Magnetic Resonance Imaging and More]), Disease Severity (Mild or Stable, Moderate, Severe or Vision-Threatening, and More), End User (Hospitals, Specialty Neurology Clinics, Ambulatory Surgical Centers), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Pseudotumor Cerebri Market Trends and Insights

Rising Obesity-Associated IIH Incidence: The Core Demand Engine

IIH follows the obesity burden across many populations. A Victoria, Australia, population study reported that age-standardized IIH incidence increased from 0.86 per 100,000 person-years in 2010-2014 to 6.53 per 100,000 in 2020-2023. Females aged 18-39 experienced a 62-fold increase over the study period. In the United States, prevalence was 3.44 per 10,000 women aged 18-55, with higher prevalence in areas that also have high obesity levels. The Pseudotumor Cerebri Market therefore has a larger diagnosed patient base where obesity remains unmanaged. Weight reduction of 5-10% can normalize intracranial pressure and can lead to remission for some patients. South and Southeast Asian populations may face a shorter period between rising obesity and clinical recognition as their obesity patterns move closer to those seen in Western countries.

Expansion of Neuro-Ophthalmology Diagnostic Capacity: OCT as the Market-Structuring Tool

OCT is becoming central to IIH monitoring because it supports repeated, noninvasive assessment of retinal nerve fiber layer thickness. A 2025 study found that OCT retinal nerve fiber layer measurement performed better than fundus imaging and intracranial pressure measurement when monitoring the course of IIH. This shift supports earlier detection of papilledema changes and gives clinicians more information before considering invasive testing. A 2026 study found that an OCT-based telemedicine model could effectively manage IIH patients and produced outcomes comparable with in-person specialist care. The Pseudotumor Cerebri Market benefits when monitoring reaches patients outside major urban specialist centers. Revised diagnostic criteria are also encouraging wider use of MRI venography beyond tertiary hospitals.

Absence of a Broadly Approved Disease-Specific Pharmacotherapy

No pharmacotherapy has a broad regulatory approval specifically for IIH. Acetazolamide remains a common first-line treatment, but it is used off label and can be difficult for patients to tolerate. A 2025 review reported that the IIHTT had a 10% discontinuation rate, while another randomized trial recorded discontinuation rates as high as 48% because of paresthesia, metabolic acidosis, and kidney stone complications. Inconsistent coverage can lead some payers to treat treatment options as experimental or restrict formulary access. Invex Therapeutics ended the IIH EVOLVE Phase III trial in fiscal year 2024 after only 13 of 240 planned patients had enrolled. This shows how difficult registration-directed trials remain when the regulatory pathway is unclear. The Pseudotumor Cerebri Market will continue to rely heavily on lower-margin generic medicines until a disease-specific approval is available.

Other drivers and restraints analyzed in the detailed report include:

1. Emerging GLP-1 and Metabolic Therapies: A Category in Formation
2. Increasing Use of Venous Sinus Stenting: From Last Resort to Preferred Surgery
3. Diagnostic Delay and Specialist Shortages

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Treatment accounted for 74.31% of the Pseudotumor Cerebri Market size in 2025, reflecting the continuing role of medicines, surgery, and supportive care across the full treatment pathway. Acetazolamide remains the main pharmacological option and is commonly prescribed from 500 mg twice daily to 4 grams per day. Topiramate is used as a second-line option because it can lower intracranial pressure and support weight management. Corticosteroids remain a short-term bridging option before definitive surgery in acute cases. Shunting and optic nerve sheath fenestration remain necessary for patients whose disease does not respond to medical care. Venous sinus stenting is taking a larger role in the surgical pathway as evidence and reimbursement develop.

Diagnostic Modality is forecast to grow at an 8.58% CAGR through 2031 in the Pseudotumor Cerebri Market. The segment is shifting from lumbar puncture toward noninvasive OCT, MRI, magnetic resonance venography, and OCT angiography. MRI venography is becoming standard in initial assessment, while OCT supports longitudinal monitoring. The 2025 OCT study supports this movement because it found better tracking performance than fundus imaging and intracranial pressure measurement. Supportive and disease-modifying care includes weight-management programs, bariatric surgery referral, and GLP-1 receptor agonists. Tirzepatide has potential relevance because its dual GIP and GLP-1 action aligns sustained weight loss with lower intracranial pressure. These care options expand the range of services used by monitored patients.

Complete Report Scope:

• By Offering
  • Treatment
    • Medication
      • Diuretics
      • Anticonvulsants
      • Corticosteroids
      • Other Medications
    • Surgical Procedures
    • Supportive and Disease-Modifying Care
  • Diagnostic Modality
    • Magnetic Resonance Imaging and Magnetic Resonance Venography
    • Computed Tomography and Computed Tomography Venography
    • Lumbar Puncture and Opening-Pressure Measurement
    • Fundoscopy and Papilledema Assessment
    • Optical Coherence Tomography
    • Other Diagnostic Modalities
• By Disease Severity
  • Mild or Stable Disease
  • Moderate Disease
  • Severe or Vision-Threatening Disease
  • Fulminant Disease
  • Medically Refractory Disease
• By End User
  • Hospitals
  • Specialty Neurology Clinics
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 42.61% of global revenue in 2025 and remains the main clinical and regulatory center for the Pseudotumor Cerebri Market. The March 2026 River Stent Humanitarian Device Exemption established a U.S. regulatory route for severe refractory IIH. IIH prevalence in U.S. women aged 18-55 was 3.44 per 10,000 and was higher in states with greater obesity levels. Canada and Mexico remain secondary contributors as referral systems develop. Europe is the second-largest regional area. The United Kingdom and Germany lead in clinical protocol development and trial activity, while the UK hosts both the IIH-Advance tirzepatide study and the OCT telemedicine validation work.

Asia-Pacific is projected to grow at an 8.85% CAGR through 2031, making it the fastest-growing regional part of the Pseudotumor Cerebri Market. Growth reflects stronger infrastructure and clinical awareness as well as increased incidence. Japan's estimated annual incidence was 0.03 per 100,000, compared with 0.5-7.8 per 100,000 in Western populations. This difference may reflect phenotype differences and diagnostic gaps created by criteria developed around Western populations. China issued its first national IIH diagnostic and treatment consensus in May 2025 and identified high misdiagnosis among ophthalmologists. Indian patients often present with vitamin D deficiency and anemia alongside IIH, which may require region-specific diagnostic thresholds. Victoria data show that the burden in some Asia-Pacific settings may already be close to Western levels but undercounted.

The Middle East and Africa and South America remain early-stage areas for the Pseudotumor Cerebri Market. Saudi Arabia, the United Arab Emirates, and Kuwait are expanding specialist neurology and ophthalmology services, while obesity-related IIH is receiving greater attention at tertiary referral hospitals. South African academic hospitals manage complex cases, but health-system fragmentation limits the treated population. Brazil supports regional activity through academic neurological centers connected to the public SUS system. Access to MRI venography and OCT differs between public and private settings. Buenos Aires is emerging as a secondary diagnostic center within Argentina's private sector. Formal IIH diagnostic guidelines are the key requirement for measurable expansion across both regions.

1. Alembic Pharmaceuticals
2. B. Braun
3. Canon
4. Carl Zeiss
5. Eli Lilly and Company
6. GE HealthCare Technologies Inc.
7. Integra LifeSciences
8. Koninklijke Philips
9. Lannett
10. Medtronic
11. Novo Nordisk
12. Sandoz Group AG
13. Serenity Medical, Inc.
14. Siemens Healthineers
15. Sophysa
16. Spiegelberg
17. Strides Pharma Science
18. Sun Pharmaceuticals Industries
19. Taro Pharmaceutical Industries Ltd.
20. Teva Pharmaceutical Industries
21. Topcon
22. Viatris
23. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Obesity-Associated IIH Incidence
  • 4.2.2 Increasing Recognition of Vision-Threatening Disease
  • 4.2.3 Expansion of Neuro-Ophthalmology Diagnostic Capacity
  • 4.2.4 Increasing Use of Venous Sinus Stenting for Refractory Disease
  • 4.2.5 Emerging GLP-1 and Metabolic Therapies for Disease Modification
  • 4.2.6 Increasing Adoption of Non-Invasive Intracranial Pressure Monitoring
• 4.3 Market Restraints
  • 4.3.1 Absence of a Broadly Approved Disease-Specific Pharmacotherapy
  • 4.3.2 Diagnostic Delay and Specialist Shortages
  • 4.3.3 Variable Surgical Evidence and Reintervention Risk
  • 4.3.4 Reimbursement Fragmentation for Off-Label and Multidisciplinary Care
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 Treatment
    • 5.1.1.1 Medication
      • 5.1.1.1.1 Diuretics
      • 5.1.1.1.2 Anticonvulsants
      • 5.1.1.1.3 Corticosteroids
      • 5.1.1.1.4 Other Medications
    • 5.1.1.2 Surgical Procedures
    • 5.1.1.3 Supportive and Disease-Modifying Care
  • 5.1.2 Diagnostic Modality
    • 5.1.2.1 Magnetic Resonance Imaging and Magnetic Resonance Venography
    • 5.1.2.2 Computed Tomography and Computed Tomography Venography
    • 5.1.2.3 Lumbar Puncture and Opening-Pressure Measurement
    • 5.1.2.4 Fundoscopy and Papilledema Assessment
    • 5.1.2.5 Optical Coherence Tomography
    • 5.1.2.6 Other Diagnostic Modalities
• 5.2 By Disease Severity
  • 5.2.1 Mild or Stable Disease
  • 5.2.2 Moderate Disease
  • 5.2.3 Severe or Vision-Threatening Disease
  • 5.2.4 Fulminant Disease
  • 5.2.5 Medically Refractory Disease
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Neurology Clinics
  • 5.3.3 Ambulatory Surgical Centers
  • 5.3.4 Other End Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Alembic Pharmaceuticals Limited
  • 6.3.2 B. Braun Melsungen AG
  • 6.3.3 Canon Medical Systems Corporation
  • 6.3.4 Carl Zeiss Meditec AG
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 GE HealthCare Technologies Inc.
  • 6.3.7 Integra LifeSciences Holdings Corporation
  • 6.3.8 Koninklijke Philips N.V.
  • 6.3.9 Lannett Company, Inc.
  • 6.3.10 Medtronic plc
  • 6.3.11 Novo Nordisk A/S
  • 6.3.12 Sandoz Group AG
  • 6.3.13 Serenity Medical, Inc.
  • 6.3.14 Siemens Healthineers AG
  • 6.3.15 Sophysa
  • 6.3.16 Spiegelberg GmbH & Co. KG
  • 6.3.17 Strides Pharma Science Limited
  • 6.3.18 Sun Pharmaceutical Industries Ltd.
  • 6.3.19 Taro Pharmaceutical Industries Ltd.
  • 6.3.20 Teva Pharmaceutical Industries Ltd.
  • 6.3.21 Topcon Corporation
  • 6.3.22 Viatris Inc.
  • 6.3.23 Zydus Lifesciences Limited

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment